The estimated Net Worth of Sjoerd S Vollebregt is at least $1.29 Milion dollars as of 16 November 2020. Mr. Vollebregt owns over 9,440 units of Mylan NV stock worth over $914,688 and over the last 7 years he sold MYL stock worth over $0. In addition, he makes $380,006 as Non-Executive Independent Director at Mylan NV.
Sjoerd has made over 5 trades of the Mylan NV stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 9,440 units of MYL stock worth $149,624 on 16 November 2020.
The largest trade he's ever made was buying 34,000 units of Mylan NV stock on 13 August 2019 worth over $642,600. On average, Sjoerd trades about 9,618 units every 165 days since 2017. As of 16 November 2020 he still owns at least 57,709 units of Mylan NV stock.
You can see the complete history of Mr. Vollebregt stock trades at the bottom of the page.
Sjoerd S. Vollebregt serves as Non-Executive Independent Director of the Company. Mr. Vollebregt has served as chairman of the supervisory board of Heijmans N.V., a Euronext Amsterdam listed company that operates in property development, residential building, non-residential building, roads and civil engineering since 2015. In March 2020, Mr. Vollebregt began serving as chair of the supervisory board of Joulz B.V., a private company that provides medium voltage electricity infrastructure and equipment in Europe, and is a portfolio company of 3i Group plc, a global investment management business listed on the London Stock Exchange. Mr. Vollebregt also serves as chairman of the Economic Development Board of Drecht Cities, a strategic collaboration between business, education and government in Drecht Cities, Netherlands, since December 2016. Mr. Vollebregt was chairman and chief executive officer of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014, which was an Amsterdam Stock Exchange-listed industrial group (until 2008), that was a global provider of knowledge-based maintenance, modification and asset integrity products and services for oil related industries, food and textile equipment manufacturer; and chief executive officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary from 2010 to 2014. Previously, Mr. Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016; chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments and structures for launchers from 2015 to 2019; and held various other senior positions at Exel plc, Ocean plc, Intexo Holding and Royal Van Ommeren. Mr. Vollebregt will not serve as a director of Viatris upon closing of the Combination.
As the Non-Executive Independent Director of Mylan NV, the total compensation of Sjoerd Vollebregt at Mylan NV is $380,006. There are 7 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.
Sjoerd Vollebregt is 65, he's been the Non-Executive Independent Director of Mylan NV since 2017. There are 4 older and 8 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
Sjoerd's mailing address filed with the SEC is BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, , HATFIELD, HERTFORDSHIRE, X0, AL10 9UL.
Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher oraz Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Mylan NV executives and other stock owners filed with the SEC include: